Czech/SlovakiaCzech RepublicSlovakia

Risks are Assessed Case-by-case

16.09.2003

The Czech Republic is in the eye of the storm in the confrontation between supporters and opponents of GMOs (see also page 20). EuroBiotechNews spoke with Libor Ambrozek, Minister for the Environment of the Czech Republic, about the postponed decision on Monsanto's application to approve of its Bt maize.

What were the reasons to hand the decision over to an independent expert group?
The administrative procedure of assessing the applications for the use of GMOs is in every case complex, that is to ensure that all the potential risks and benefits are considered. The Competent Authority handling the applications and regulating the use of GMOs in the Czech Republic is the Department of Environmental Risks at the Ministry of the Environment (MoE). It co-operates with the Ministry of Health in respect of risks for human health and with the Ministry of Agriculture as regards the agricultural risk, animal health, crops and feed stuffs. Advisory body to the MoE is the Czech Commission for the Use of GMOs and Products. The marketing approval for Monsanto´s Bt maize issued by the Department of Environmental Risks in March 2003 was rather limited. It covered only planting and processing, but not import and export of the maize. According to the opinion of the Ministry of the Agriculture, strict isolation distances were required for fields with Bt maize. Monsanto appealed against the restrictive conditions of the approval. On the opposite side, Greenpeace, appealed against the approval as such. Both appeals were examined by the committee of lawyers and I consequently repealed the approval because the conditions were insufficiently substantiated. The case was referred back to the department to re-negotiate and substantiate the conditions of the use of Bt maize with the Ministry of Agriculture.
Who is in this expert group and when do you expect a decision?
Members of the Commission for the use of GMOs are representatives of administrative authorities, scientists and representatives of NGOs. The list of the members is published on the website of the MoE. A new decision should be issued at the end of September.
How does the MoE consider the risks from 'cross-pollination'?
Risk are always assessed case-by-case. As far as maize is concerned, cross-pollination could present a risk to neighbouring farmers as regards potential contamination of their final product. The environmental risks considered to be low. Maize has no sexually compatible relatives in the indigenous flora of the Czech Republic. It does not survive winters and the seeds of maize used by farmers are hybrids, which refers to the special technology of seed production. To minimize potential economic losses from the admixtures of GM in non-GM crops, the Ministry of Agriculture in co-operation with the MoE prepares detailed guidelines for the coexistence of genetically modified crops with conventional and organic farming in accordance with the recommendation of European Commission from July 2003.
Can you characterize the public opinion on GM food in the Czech Republic?
Public opinion on GM food in the Czech Republic is about the same as in other European countries. The public supports labelling of GMO products. The genetically modified crops that are on the market in other countries do not bring any advantage for consumers, so the public does not see any specific reason to buy them.
Do you share environmentalists' claims that Monsanto uses the Czech Republic as a key to open the whole EU GMO market?
The applications for GM crops submitted by Monsanto in the Czech Republic and approved by the MoE are the same as in other EU member states. The MoE approved field trials with Bt maize MON 810, which has already been granted marketing approval in the EU, and field trials with Roundup Ready maize which is also tested in EU member states. Field trials with Roundup Ready wheat applied for by Monsanto have not been approved of. The marketing approval for Monsanto's Roundup Ready soybeans is equivalent to the authorization already granted in the EU.
Thank you very much, Mr. Ambrozek!

Czech/SlovakiaCzech RepublicSlovakia

07.03.2012

The Czech government has beefed up its investments in biotech with the help of EU structural funds. In February, the country’s Education Minister Josef Dobes gave the go-ahead for the Biocev centre in Vestec near Prague. Although...

Czech/SlovakiaCzech RepublicSlovakia

05.12.2011

Brno – Czech Prime Minister Petr Necas has officially inaugurated the first of six European Technology Institutes slated to be launched in the Czech Republic with help from European FEDER funds. Although construction of the €200m...

Czech/SlovakiaCzech RepublicSlovakia

01.10.2011

Prague – Czech drug developer VUAB Pharma a.s. has joined CzechBio. The company, which has its headquarters in Roztoky near Prague, became the 35th member of the Czech biotechnology industry association in September. VUAB...

Czech/SlovakiaCzech RepublicSlovakia

09.08.2011

Praque – A team of researchers headed by Dr. Valdimir Kral, Director of Chemical Development at Sanofi-Aventis’ Czech research unit Zentiva Development sro, has presented a new targeted drug delivery system that couples combined...

Czech/SlovakiaCzech RepublicSlovakia

01.06.2011

Brno – Plans for building a Central European Insitute of Technology (CEITEC) in Brno look set to take a big step closer to becoming reality. In mid-May, CEITEC representatives announced that EU financing for the EUR260m...

Czech/SlovakiaCzech RepublicSlovakia

03.11.2010

Plzen – Czech antibody discovery and development specialist AbCheck s.r.o. has signed its first contract with a big pharma company. In October, the yearling Czech spin-off from German antibody drug developer Affimed GmbH...

Czech/SlovakiaCzech RepublicSlovakia

13.09.2010

Prague – CzechInvest has called on Czech high-tech companies in the field of ICT, bio­technology, clean technology and micro­electronics to apply for the Czech Technology Accelerator programme. Under the third call, which was...

Czech/SlovakiaCzech RepublicSlovakia

02.07.2010

Prague – Czech researchers from Charles University in Prague have discovered a molecular biomarker that helps to predict toxicity and a higher risk for adverse effects in children with juvenile arthritis that are treated with...

Czech/SlovakiaCzech RepublicSlovakia

12.05.2010

Prague – Czech biotech company Lenti­Kats AS has begun worldwide commercialisation of a patented, cost-effective encapsulation technology for use in the food and bio­pharmaceuticals industry. The company has discovered a way to...

Czech/SlovakiaCzech RepublicSlovakia

12.05.2010

Sofia – Bulgaria’s parliament has approved a law that will in effect ban any cultivation of GMO crops in the country. “There will be no field on the country’s territory where GMOs can be cultivated,” said Kostadin Yazov from the...

Displaying results 1 to 10 out of 70

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-czech-slovakia/article/risks-are-assessed-case-by-case.html

Print Magazine

Event Video

All videos

Events

All Events

Stock list

All quotes

TOP

  • MOLOGEN6.46 EUR16.82%
  • CYTOS0.17 CHF13.33%
  • WILEX2.25 EUR7.14%

FLOP

  • 4SC0.87 EUR-1.14%
  • CYTOTOOLS31.45 EUR-0.47%
  • ADDEX3.20 CHF0.00%

TOP

  • BIOFRONTERA2.88 EUR30.9%
  • ADDEX3.20 CHF3.2%
  • HBM84.00 CHF0.6%

FLOP

  • CYTOS0.17 CHF-29.2%
  • PAION2.22 EUR-27.2%
  • 4SC0.87 EUR-25.6%

TOP

  • SANTHERA82.40 CHF2085.7%
  • CO.DON2.58 EUR163.3%
  • PAION2.22 EUR146.7%

FLOP

  • CYTOS0.17 CHF-95.7%
  • 4SC0.87 EUR-50.8%
  • THERAMETRICS0.07 CHF-50.0%

No liability assumed, Date: 20.10.2014


Current issue

All issues

Product of the week

Products